Summary

Europe pharmaceutical solvent market is expected to reach USD 2.08 billion by 2032 from USD 1.38 billion in 2024, growing at a CAGR of 5.3% in the forecast period of 2025 to 2032.
Market Segmentation:
Europe pharmaceutical solvent market, By Product (Alcohols, Aromatic Hydrocarbons, Ketones, Ethers, Amine, Esters, Chlorinated Solvents, and Others) and Application (Pharmaceutical, Research Laboratories, Chemical and Others), Country (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Belgium, Austria, Ireland, Norway, Poland, Rest Of Europe) -Industry Trends & Forecast To 2032

Overview of Europe Pharmaceutical Solvent Market Dynamics:

Driver

• Increase in the manufacturing of innovative generic medications, especially within emerging economies

Restraint
• Adoption of green solvents poses operational and technical challenges
Opportunity

•
Expansion of biosimilars and high-potency drugs
Market Players

The key market players for Europe pharmaceutical solvent market are listed below:
• BASF

• Shell plc

• Bayer AG

• Merck & Co., Inc.

• Clariant

• Mitsoi

• ExxonMobil Corporation

• Mitsubishi Chemical Corporation

• Dow

• Nouryon

• Braskem SA

• DuPont

• Eastman Chemical Company

• LyondellBasell Industries N.V

• Actylis

• SK Global Chemical Co., Ltd.

• Carl Roth

• Chemco

• PCC

• Advion

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE EUROPE PHARMACEUTICAL SOLVENT MARKET 19
1.4 CURRENCY AND PRICING 20
1.5 LIMITATIONS 20
1.6 MARKETS COVERED 20
2 MARKET SEGMENTATION 23
2.1 MARKETS COVERED 23
2.2 GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 DBMR TRIPOD DATA VALIDATION MODEL 25
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.6 MARKET APPLICATION COVERAGE GRID 29
2.7 MULTIVARIATE MODELLING 30
2.8 DBMR MARKET POSITION GRID 31
2.9 VENDOR SHARE ANALYSIS 32
2.10 SECONDARY SOURCES 33
2.11 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 36
4.1 PORTER’S FIVE FORCES 39
4.2 PESTLE ANALYSIS 40
4.3 CLIMATE CHANGE SCENARIO – EUROPE PHARMACEUTICAL SOLVENT MARKET 41
4.3.1 ENVIRONMENTAL CONCERNS 41
4.3.2 INDUSTRY RESPONSE 41
4.3.3 GOVERNMENT’S ROLE 41
4.4 PRICING ANALYSIS – EUROPE PHARMACEUTICAL SOLVENT MARKET 43
4.4.1 RAW MATERIAL COSTS 43
4.4.2 PURITY AND GRADE 43
4.4.3 REGULATORY COMPLIANCE COSTS 43
4.4.4 REGIONAL PRICING VARIABILITY 43
4.4.5 SUPPLY CHAIN & LOGISTICS 43
4.4.6 COMPETITIVE LANDSCAPE 44
4.4.7 FORECASTED PRICING TRENDS (2025–2032) 44
4.5 PRODUCTION CAPACITY OVERVIEW – EUROPE PHARMACEUTICAL SOLVENT MARKET 45
4.5.1 KEY PRODUCTION HUBS 45
4.5.2 CAPACITY UTILIZATION TRENDS 45
4.5.3 IMPACT OF GREEN CHEMISTRY INITIATIVES 45
4.5.4 CAPACITY CONSTRAINTS & CHALLENGES 45
4.6 RAW MATERIAL COVERAGE 46
4.6.1 IMPORT-EXPORT ANALYSIS 46
4.6.2 PRODUCTION–CONSUMPTION ANALYSIS 47
4.7 SUPPLY CHAIN ANALYSIS – EUROPE PHARMACEUTICAL SOLVENT MARKET 48
4.7.1 OVERVIEW 48
4.7.2 LOGISTIC COST SCENARIO 48
4.7.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 49
4.8 TARIFFS AND ITS IMPACT ON THE MARKET – EUROPE PHARMACEUTICAL SOLVENT MARKET 50
4.8.1 DEFINITION AND IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 50
4.8.2 GLOBAL VS. REGIONAL TARIFF STRUCTURES 50
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 50
4.8.4 TARIFF REGULATIONS IN KEY MARKETS 50
4.8.4.1 MEDICARE/MEDICAID TARIFF POLICIES 50
4.8.4.2 CMS PRICING MODELS 50
4.8.4.3 OTHER COUNTRY-SPECIFIC SYSTEMS 50
4.8.4.4 TARIFFS ON MEDICAL DEVICES & EQUIPMENT 51
4.8.4.5 IMPORT/EXPORT DUTIES ON MEDICAL EQUIPMENT 51
4.8.4.6 IMPACT ON PRICING AND AVAILABILITY OF HIGH-END MEDICAL TECHNOLOGY 51
4.8.5 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 51
4.8.6 TARIFF EXEMPTIONS AND INCENTIVES 51
4.8.7 DUTY-FREE IMPORTS FOR ESSENTIAL MEDICINES AND VACCINES 51
4.8.8 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 51
4.8.9 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 51
4.9 VENDOR SELECTION CRITERIA: 52
5 REGULATION COVERAGE – EUROPE PHARMACEUTICAL SOLVENT MARKET 53
5.1 PRODUCT CODES 53
5.2 CERTIFIED STANDARDS 53
5.3 SAFETY STANDARDS 54
5.3.1 MATERIAL HANDLING & STORAGE 54
5.3.2 TRANSPORT & PRECAUTIONS 54
5.3.3 HAZARD IDENTIFICATION 54
 
6 MARKET OVERVIEW 55
6.1 DRIVER 57
6.1.1 INCREASE IN THE MANUFACTURING OF INNOVATIVE GENERIC MEDICATIONS, ESPECIALLY WITHIN EMERGING ECONOMIES 57
6.1.2 INCREASE IN DEMAND FOR ALCOHOL SOLVENTS FOR MANUFACTURING OF VARIOUS DRUGS. 58
6.1.3 GROWTH IN PHARMACEUTICAL, AND HEALTHCARE SECTOR ACROSS THE EUROPE 58
6.1.4 RISE IN ADOPTION OF GREEN MATERIALS AND CHEMICALS FOR DRUG 59
6.2 RESTRAINT 60
6.2.1 ADOPTION OF GREEN SOLVENTS POSES OPERATIONAL AND TECHNICAL CHALLENGES 60
6.2.2 SHORTAGE OF SPECIALIZED WORKFORCE HINDERING SOLVENT PRODUCTION EFFICIENCY 61
6.3 OPPORTUNITY 62
6.3.1 EXPANSION OF BIOSIMILARS AND HIGH-POTENCY DRUGS 62
6.3.2 RISE IN CLINICAL TRIALS AND R&D INVESTMENTS 63
6.3.3 INCREASING FOCUS ON PERSONALIZED MEDICINE AND ORPHAN DRUGS. 64
6.4 CHALLENGES 65
6.4.1 COMPETITION FROM ALTERNATIVE FORMULATION TECHNOLOGIES 65
6.4.2 HEALTH AND SAFETY CONCERNS REGARDING PHARMACEUTICAL SOLVENTS 66
7 EUROPE PHARMACEUTICAL SOLVENT MARKET, BY PRODUCT 67
7.1 OVERVIEW 68
7.2 ALCOHOLS 73
7.2.1 METHANOL 74
7.2.2 ETHANOL 74
7.2.3 1-BUTANOL 74
7.2.4 2-BUTANOL 74
7.2.5 2-METHOXYETHANOL 74
7.2.6 3-METHYL-1-PROPANOL 74
7.2.7 2-METHYL-1-PROPANOL 74
7.2.8 1-PENTANOL 74
7.2.9 1-PROPANOL 74
7.2.10 2-PROPANOL (ISOPROPYL ALCOHOL) 74
7.2.11 ISOPROPANOL 74
7.2.12 PROPYLENE GLYCOL 74
7.2.13 OTHERS 74
 
7.3 AROMATIC HYDROCARBONS 75
7.3.1 TOLUENE 75
7.3.2 XYLENE 75
7.3.3 ETHYLBENZENE 75
7.3.4 OTHERS 75
7.4 KETONES 76
7.4.1 ACETONE 76
7.4.2 CYCLOHEXANONE 76
7.4.3 METHYL ETHER KETONE 76
7.4.4 METHYL ETHYL KETONE 76
7.4.5 METHYL ISOBUTYL KETONE 76
7.4.6 OTHERS 76
7.5 ETHERS 77
7.5.1 DIETHYL ETHER 77
7.5.2 TETRAHYDROFURAN 77
7.5.3 METHOXYMETHANE 77
7.5.4 METHYL TERT-BUTYL ETHER 77
7.5.5 POLYETHYLENE GLYCOL 77
7.5.6 ANISOLE 77
7.5.7 DI-N-PROPYL ETHER 77
7.5.8 OTHERS 77
7.6 AMINE 78
7.6.1 MONOETHANOLAMIDE (MEA) 78
7.6.2 ANILINE 78
7.6.3 DIETHANOLAMINE (DEA) 78
7.6.4 METHYL DIETHANOLAMINE (MDEA) 78
7.6.5 TRIMETHYLAMINE 78
7.6.6 OTHERS 78
7.7 ESTERS 79
7.7.1 ACETYL ACETATE 79
7.7.2 ETHYL ACETATE 79
7.7.3 BUTYL ACETATE 79
7.7.4 OTHERS 79
7.8 CHLORINATED SOLVENTS 80
7.8.1 TRICHLOROETHYLENE (TCE) 80
7.8.2 DICHLOROMETHANE 80
7.8.3 PERCHLOROETHYLENE (PCE) 80
7.8.4 TRICHLOROETHANE (TCA) 80
7.8.5 CARBON TETRACHLORIDE 80
7.8.6 OTHERS 80
7.9 OTHERS 80
8 EUROPE PHARMACEUTICAL SOLVENT MARKET, BY APPLICATION 81
8.1 OVERVIEW 82
8.2 PHARMACEUTICAL 85
8.3 RESEARCH LABORATORIES 85
8.4 CHEMICAL 85
8.5 OTHERS 85
9 EUROPE PHARMACEUTICAL SOLVENT MARKET BY COUNTRIES 86
9.1 EUROPE 86
9.1.1 SWITZERLAND 88
9.1.2 ITALY 93
9.1.3 GERMANY 98
9.1.4 FRANCE 103
9.1.5 U.K. 108
9.1.6 SPAIN 113
9.1.7 BELGIUM 118
9.1.8 NETHERLANDS 123
9.1.9 RUSSIA 128
9.1.10 TURKEY 133
9.1.11 LUXEMBURG 138
9.1.12 REST OF EUROPE 143
10 EUROPE PHARMACEUTICAL SOLVENT MARKET: COMPANY LANDSCAPE 145
10.1 COMPANY SHARE ANALYSIS: EUROPE 145
11 SWOT ANALYSIS 146
12 COMPANY PROFILES 147
12.1 BASF CORPORATION 147
12.1.1 COMPANY SNAPSHOT 147
12.1.2 PRODUCT PORTFOLIO 147
12.1.3 RECENT UPDATES 150
12.2 SHELL PLC 151
12.2.1 COMPANY SNAPSHOT 151
12.2.2 REVENUE ANALYSIS 151
12.2.3 PRODUCT PORTFOLIO 152
12.2.4 RECENT DEVELOPMENT 157
 
12.3 BAYER AG 158
12.3.1 COMPANY SNAPSHOT 158
12.3.2 REVENUE ANALYSIS 158
12.3.3 PRODUCT PORTFOLIO 159
12.3.4 RECENT DEVELOPMENT 159
12.4 MERCK KGAA 160
12.4.1 COMPANY SNAPSHOT 160
12.4.2 REVENUE ANALYSIS 160
12.4.3 PRODUCT PORTFOLIO 161
12.4.4 RECENT UPDATES 163
12.5 CLARIANT 164
12.5.1 COMPANY SNAPSHOT 164
12.5.2 REVENUE ANALYSIS 165
12.5.3 PRODUCT PORTFOLIO 165
12.5.4 RECENT DEVELOPMENT 167
12.6 ACTYLIS 168
12.6.1 COMPANY SNAPSHOT 168
12.6.2 PRODUCT PORTFOLIO 168
12.6.3 RECENT UPDATES 169
12.7 ADVION INTERCHIM SCIENTIFIC 170
12.7.1 COMPANY SNAPSHOT 170
12.7.2 PRODUCT PORTFOLIO 170
12.7.3 RECENT DEVELOPMENT 171
12.8 BRASKEM 172
12.8.1 COMPANY SNAPSHOT 172
12.8.2 PRODUCT PORTFOLIO 172
12.8.3 RECENT DEVELOPMENT 173
12.9 CARL ROTH GMBH + CO. KG 174
12.9.1 COMPANY SNAPSHOT 174
12.9.2 PRODUCT PORTFOLIO 174
12.9.3 RECENT DEVELOPMENT/NEWS 175
12.10 CHEMCO UK 176
12.10.1 COMPANY SNAPSHOT 176
12.10.2 PRODUCT PORTFOLIO 176
12.10.3 RECENT DEVELOPMENT 177
12.11 DOW 178
12.11.1 COMPANY SNAPSHOT 178
12.11.2 REVENUE ANALYSIS 178
12.11.3 PRODUCT PORTFOLIO 179
12.11.4 RECENT DEVELOPMENT 179
12.12 DUPONT 180
12.12.1 COMPANY SNAPSHOT 180
12.12.2 REVENUE ANALYSIS 180
12.12.3 PRODUCT PORTFOLIO 181
12.12.4 RECENT DEVELOPMENT 181
12.13 EASTMAN CHEMICAL COMPANY 182
12.13.1 COMPANY SNAPSHOT 182
12.13.2 REVENUE ANALYSIS 182
12.13.3 PRODUCT PORTFOLIO 183
12.13.4 RECENT DEVELOPMENT 183
12.14 EXXON MOBIL CORPORATION 184
12.14.1 COMPANY SNAPSHOT 184
12.14.2 REVENUE ANALYSIS 184
12.14.3 PRODUCT PORTFOLIO 185
12.14.4 RECENT DEVELOPMENT 186
12.15 LYONDELLBASELL INDUSTRIES HOLDINGS B.V. 187
12.15.1 COMPANY SNAPSHOT 187
12.15.2 REVENUE ANALYSIS 187
12.15.3 PRODUCT PORTFOLIO 188
12.15.4 RECENT DEVELOPMENT 189
12.16 MITSUI CHEMICALS, INC. 190
12.16.1 COMPANY SNAPSHOT 190
12.16.2 REVENUE ANALYSIS 190
12.16.3 PRODUCT PORTFOLIO 191
12.16.4 RECENT DEVELOPMENT 192
12.17 NOURYON 193
12.17.1 COMPANY SNAPSHOT 193
12.17.2 PRODUCT PORTFOLIO 193
12.17.3 RECENT UPDATES 194
12.18 PCC GROUP 195
12.18.1 COMPANY SNAPSHOT 195
12.18.2 PRODUCT PORTFOLIO 195
12.18.3 RECENT UPDATES 198
12.19 SEQENS 199
12.19.1 COMPANY SNAPSHOT 199
12.19.2 PRODUCT PORTFOLIO 199
12.19.3 RECENT DEVELOPMENT 199
 
12.20 SK CHEMICALS 200
12.20.1 COMPANY SNAPSHOT 200
12.20.2 PRODUCT PORTFOLIO 200
12.20.3 RECENT DEVELOPMENT 201
13 QUESTIONNAIRE 202
14 RELATED REPORTS 204